This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a biomarker-guided predictive care company, has presented data showing its FDA-cleared, non-invasive, biomarker-based technology for remote heartfailure monitoring detected twice as many heartfailure events as compared to the weight-based standard of care. Bodyport Inc., Image courtesy: Bodyport Inc.
recently announced that Digitiva, a non-invasive digital health solution for heartfailure management, has been listed with the U.S. a smartphone app designed for heartfailure patients and built on the Welldoc, Inc. a smartphone app designed for heartfailure patients and built on the Welldoc, Inc.
Data supporting the role of primary prevention ICDs in patients with heartfailure were generated by rigorous randomized controlled trials (RCTs).1 1 During this time period, numerous advances in ICD technology, care, and follow-up have resulted in unequivocal improvement in the outcomes of patients with an ICD.
CMS has reviewed the CardiAMP HeartFailure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP HeartFailure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,
healthcare providers can now detect Low EF, a key heartfailure indicator, in 15 seconds using an Eko stethoscope during a routine physical examination. As a result, many heartfailure cases go undiagnosed until symptoms force a specialist or emergency hospital visit, leading to worse patient outcomes and exacerbated healthcare costs.2
The DRAIN-HF study will evaluate the Aortix percutaneous mechanical circulatory support (pMCS) technology in patients with acute decompensated heartfailure (ADHF) who are unresponsive to standard medical therapy. I am excited to be able to include the advanced heartfailure patients in the trial," commented Dr. Grafton.
Remote patient monitoring in heartfailure (HF). Abstract Aims Methods of non-invasive remote patient monitoring (RPM) for heartfailure (HF) remain diverse. Modernizing RPM with advanced technologies like non-invasive sensors, artificial intelligence, and cardiac telerehabilitation could enhance its potential.
Genesis is the latest advancement in Robotic Magnetic Navigation technology. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern.
Eighty percent of heart attacks and strokes are preventable. partially because its key risk factor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heart attack or stroke. Yet, CVD remains the leading cause of death in the U.S.,
Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. These patients saw more than a 17% lower rate of heart death equivalents at up to two years compared to control patients treated with heartfailure medication alone (2.9%
We look forward to bringing our AI technology to meet patients and physicians where they are, ultimately benefiting both worldwide.” The companies will also work together to validate the clinical utility of the integrated solution and seek regulatory clearance to bring this technology to market. Under the agreement, InfoBionic.Ai
Such technology could make it faster and cheaper to evaluate new treatments and, ultimately, help bring successful ones to patients. Generative Artificial Intelligence (Gen AI) can rapidly and accurately screen patients for clinical trial eligibility, according to a new study from Mass General Brigham researchers.
The robotic technology represented an entirely novel way to address heart rhythm disorders in a minimally invasive procedure with the benefits of robotic precision and safety. When left untreated, arrhythmias may significantly increase the risk of stroke, heartfailure, and sudden cardiac arrest.
Henry Ford Health's Center for Structural Heart Disease team delivered its first in Michigan FDA-approved VOQUE Transcatheter Tricuspid Valve Replacement System to a heartfailure patient on February 13, 2024 at Henry Ford Hospital in Detroit. Other symptoms include swelling in the abdomen, legs or neck veins.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. The CaRi-Hearttechnology is in clinical use in the UK, European Union, and Australia.
This article reviews the use of digital wearable technologies for monitoring of three common cardiovascular conditions: hypertension, heartfailure, and atrial fibrillation.
FIRE1s Norm heartfailure management system offers a unique approach for patients to manage heartfailure. The company also announced Ellie McGuire, Partner at Polaris Partners, and Michael Wasserman, Partner and COO at Elevage Medical Technologies have joined its Board of Directors.
IntroductionVentricular assist devices (VADs) are lifesavers for people with advanced heartfailure. The design of these devices has undergone drastic changes over time with the latest designs being far more efficient, small, lightweight, and more user-friendly. Top countries include the USA, China, and Germany.
Luigi Caliendo explains the benefits of Robotic Technology to President Vincenzo de Luca. Luigi Caliendo explains the benefits of Robotic Technology to President Vincenzo de Luca. When left untreated, arrhythmias may significantly increase the risk of stroke , heartfailure , and sudden cardiac arrest.
(MedPage Today) -- CHICAGO -- Champions of tricuspid transcatheter edge-to-edge repair (TEER) were buoyed by 2-year results of the TRILUMINATE trial marking the first report of reduced heartfailure (HF) hospitalization for this technology.
The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (Echo) markers of diastolic dysfunction, an important component in the development of heartfailure, in hypertensive patients. Advanced HeartFailure Cardiologist, Duke Health on Feb.
mtaschetta-millane Tue, 07/16/2024 - 09:47 July 16, 2024 — Ultrahuman, a pioneer in wearable technology , launches PowerPlugs, a platform for individual apps and plugins built on top of Ultrahuman’s health and wellness data stack. AFib is the most common type of irregular heart rhythm or arrhythmia.
Edwards Lifesciences is going all-in on structural heart and heartfailure, acquiring aortic valve-maker JenaValve Technology and implantable heartfailure monitor company Endotronix for $1.2B and up to $445M in milestone payments.
This irregular heartbeat is associated with increased risks of heartfailure, dementia and stroke. These results pave the way for integration into wearable technologies, allowing early interventions and better patient outcomes. It gives early warnings on average 30 minutes before onset, with an accuracy of around 80%.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: HeartFailure Reveals that Despite Significant Efforts to Improve Acute HeartFailure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
Clinical trials and innovative technology took center stage during the month of April, racking up some record number views. New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol and Weight Using Mobile Technology 2. 24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack 10.
ObjectivesTelenursing in cardiac care leverages technology to support self-care and optimize outcomes for heartfailure patients during and beyond the pandemic.
The device is being developed as a first-in-class implantable sensor to provide daily adjunctive objective cardiac parameter measurements enabling patients and clinicians to better manage their congestive heartfailure symptoms with current medication management tools. heartfailure market is projected to be $70B annually by 2030.
At present, the main methods to treat ischemic heart disease are drug therapy, intervention and operation. These methods only alleviate symptoms of heartfailure and myocardial ischemia and improve patients' quality of life by partially restoring myocardial reperfusion.
a commercial-stage medical device company, announced today the availability of additional data, including the publication of results of the post-market phase of the BeAT-HF trial in the European Journal of HeartFailure. The manuscript is available online at the European Journal of HeartFailure website.
Bodyport Presents Preliminary Analysis of SCALE-HF 1 Study on Remote HeartFailure Monitoring at Technology and HeartFailure Therapeutics (THT) Conference 9. FDA Announces Abbott Recall of HeartMate Touch Communication System for Unintentional Pump Start and Stop 8.
Efforts to foster both intrinsic and extrinsic regenerative responses in heartfailure have once again brought iPS cell technologies to the forefront, thanks to their flexibility in reconstructing tissues in vitro and enabling researchers to investigate the biological mechanisms driving cell-fate decisions.
Research Highlights: Analyzing a patient’s voice recorded daily on a smartphone, artificial intelligence technology detected increasing fluid in their lungs — a sign of worsening heartfailure. In the trial of more than 400 adults with heartfailure.
The global health challenge posed by cardiac arrhythmias, particularly atrial fibrillation (AF), is significant, with heightened risks of stroke, heartfailure, and systemic embolism1. Traditional arrhythmia detection has often missed transient or asymptomatic episodes, relying on symptomatic presentations and episodic monitoring.
12, 2024 Physicians have a new treatment option for many of the sickest pediatric patients with heartfailure andcardiogenic shock. and Impella CP enable heart recovery as part of the world's smallest heart pump platform. with SmartAssist tim.hodson Wed, 12/18/2024 - 14:06 Dec.
We now have one more technology, on the verge of approval by the FDA. Final message WiSE CRT uses some revolutionary technology and it is a welcome addition in few eligible patients. However, advanced heartfailure therapy never means it can be achieved only by state-of-the-art technology. Reference 1. 2024.2050 2.
The same technology that enables a bullet train to travel at speeds up to 200 mph without touching its rails now keeps a failing heart pumping—and in the near future, it will do so via a wireless power connection.
mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth.
mtaschetta-millane Thu, 07/11/2024 - 10:53 July 11, 2024 — Heart Test Laboratories, Inc. Heartfailure (HF) is a growing worldwide public health issue affecting 64 million people annually 1 and is associated with high mortality, lower quality of life and reduced physical capacity while placing substantial costs on the healthcare system.
30, 2024 — HeartLung Technologies , a developer of AI tools for early detection of heart disease, lung cancer and other conditions announced that its AI-enabled Automated Cardiac Chambers Volumetry (AutoChamber) recently received “Breakthrough Medical Device” designation and marketing authorization from the U.S. “By
Early Feasibility Study (FUTURE-HF2) of its FIRE1 System for remote heartfailure monitoring. The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heartfailure.
The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heartfailure.
Early detection and intervention are essential in addressing cardiovascular diseases, and Eko is dedicated to providing accessible and scalable technologies that empower healthcare providers while improving patient care globally."
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content